Literature DB >> 17063305

Expression of liver-intestine cadherin and its correlation with lymph node metastasis in gastric cancer: can it predict N stage preoperatively?

Sung-Soo Park1, Sang-Hee Kang, Joong-Min Park, Jong-Han Kim, Sang-Cheul Oh, Ju-Han Lee, Yang-Seok Chae, Seung-Joo Kim, Chong-Suk Kim, Young-Jae Mok.   

Abstract

BACKGROUND: Reliable method to predict lymph node metastasis is not yet available. In the present study, therefore, we examined LI-cadherin expression in human gastric cancer and attempted to find its relationship with clinicopathologic data, especially with lymph node metastasis. We also analyzed the expression in preoperative biopsy specimen to uncover its possibility of prognostication for lymph node metastasis.
METHODS: The paired preoperative endoscopic biopsy and postoperative resected specimens from 208 patients who had surgically been treated for gastric cancer were retrospectively analyzed immunohistochemically for expression of LI-cadherin.
RESULTS: There were 47 (22.6%) and 161 (77.4%) tumors which had positive and negative LI-cadherin expression, respectively. LI-cadherin expression was significantly correlated with tumor histology and lymph node metastasis: Furthermore, reduced expression of LI-cadherin was closely associated with tumor progression and lymph node metastasis in human gastric carcinoma. LI-cadherin expressions in both resected tumor and preoperative endoscopic tissues were found to be independent factors associated with lymph node metastasis.
CONCLUSIONS: There is a close association between reduced expression of LI-cadherin and lymph node metastasis in human gastric cancer. Immunohistochemical study of LI-cadherin is relatively simple compared to sentinel node navigation surgery, and it could be a practical prediction method for lymph node metastasis in patients with this malignancy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17063305     DOI: 10.1245/s10434-006-9114-9

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  9 in total

Review 1.  Association between cadherin-17 expression and pathological characteristics of gastric cancer: a meta-analysis.

Authors:  Zi-Wen Long; Meng-Long Zhou; Jing-Wei Fu; Xian-Qun Chu; Ya-Nong Wang
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

2.  Gene expression profiling of metaplastic lineages identifies CDH17 as a prognostic marker in early stage gastric cancer.

Authors:  Hyuk-Joon Lee; Ki Taek Nam; Heae Surng Park; Min A Kim; Bonnie J Lafleur; Hiroyuki Aburatani; Han-Kwang Yang; Woo Ho Kim; James R Goldenring
Journal:  Gastroenterology       Date:  2010-04-13       Impact factor: 22.682

3.  Liver-intestine cadherin induction by epidermal growth factor receptor is associated with intestinal differentiation of gastric cancer.

Authors:  Naoya Sakamoto; Naohide Oue; Kazuhiro Sentani; Katsuhiro Anami; Naohiro Uraoka; Yutaka Naito; Htoo Zarni Oo; Takao Hinoi; Hideki Ohdan; Kazuyoshi Yanagihara; Kazuhiko Aoyagi; Hiroki Sasaki; Wataru Yasui
Journal:  Cancer Sci       Date:  2012-07-16       Impact factor: 6.716

4.  Aberrant loss of dickkopf-3 in gastric cancer: can it predict lymph node metastasis preoperatively?

Authors:  Joong-Min Park; Mi Kyung Kim; Kyong-Choun Chi; Jae Hyung Kim; Sang-Hoon Lee; Eun-Ju Lee
Journal:  World J Surg       Date:  2015-04       Impact factor: 3.352

5.  The contribution of cell phenotype to the behavior of gastric cancer.

Authors:  Enrico Solcia; Catherine Klersy; Alessandro Vanoli; Federica Grillo; Rachele Manca; Francesca Tava; Ombretta Luinetti; Roberto Fiocca
Journal:  Gastric Cancer       Date:  2013-01-18       Impact factor: 7.370

Review 6.  Involvement of liver-intestine cadherin in cancer progression.

Authors:  Masaaki Takamura; Satoshi Yamagiwa; Yasunobu Matsuda; Takafumi Ichida; Yutaka Aoyagi
Journal:  Med Mol Morphol       Date:  2013-01-10       Impact factor: 2.309

7.  Cadherin 17 is frequently expressed by 'sclerosing variant' pancreatic neuroendocrine tumour.

Authors:  Adam Johnson; Jesse P Wright; Zhiguo Zhao; Tatsuki Komaya; Alexander Parikh; Nipun Merchant; Chanjuan Shi
Journal:  Histopathology       Date:  2014-10-28       Impact factor: 5.087

8.  Targeting cadherin-17 inactivates Wnt signaling and inhibits tumor growth in liver carcinoma.

Authors:  Ling Xiao Liu; Nikki P Lee; Vivian W Chan; Wen Xue; Lars Zender; Chunsheng Zhang; Mao Mao; Hongyue Dai; Xiao Lin Wang; Michelle Z Xu; Terence K Lee; Irene O Ng; Yangchao Chen; Hsiang-fu Kung; Scott W Lowe; Ronnie T P Poon; Jian Hua Wang; John M Luk
Journal:  Hepatology       Date:  2009-11       Impact factor: 17.425

9.  Targeting CDH17 suppresses tumor progression in gastric cancer by downregulating Wnt/β-catenin signaling.

Authors:  Hai-bo Qiu; Li-yi Zhang; Chao Ren; Zhao-lei Zeng; Wen-jing Wu; Hui-yan Luo; Zhi-wei Zhou; Rui-hua Xu
Journal:  PLoS One       Date:  2013-03-15       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.